As part of the deal, TGen will also become a subsidiary of City of Hope's parent organization, but will remain a non-profit headquartered in Arizona.
Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
The partners are planning a joint research center at Providence Health Care's St. Paul's Hospital in Vancouver and a center of excellence in China.
The agreement lets Biotheranostics offer its CancerType ID and Breast Cancer Index genomic tests to customers through Syapse's software.
The planned program will be available at nearly 150 hospitals and care centers across the US serving approximately 12 million patients per year.
The companies plan to combine Macrogen's sequencing capabilities with Systems Imagination's analysis tools.
Strata said it will use the funds to implement the Strata Trial, a nationwide effort to increase the number of enrollments in precision medicine clinical trials.
The combined solution gives customers access to the bioinformatics tools and genomic intelligence to help them analyze data and make business decisions.
The scientific products giants are exhibiting their combined workflow next week at the European Congress of Clinical Microbiology and Infectious Disease.
The institutes will exchange investigators, form research collaborations in various areas of plant biotechnology, and start new companies together.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.